BR112020000590A2 - método de seleção de uma coleção, métodos para determinar as sequências de aminoácidos e para produzir uma cvp ou uma coleção de ácidos nucleicos, cvp, coleções de peptídeos de vacina, de ácidos nucleicos, de um ou mais vetores de expressão e coleção de vetores de expressão - Google Patents

método de seleção de uma coleção, métodos para determinar as sequências de aminoácidos e para produzir uma cvp ou uma coleção de ácidos nucleicos, cvp, coleções de peptídeos de vacina, de ácidos nucleicos, de um ou mais vetores de expressão e coleção de vetores de expressão Download PDF

Info

Publication number
BR112020000590A2
BR112020000590A2 BR112020000590-8A BR112020000590A BR112020000590A2 BR 112020000590 A2 BR112020000590 A2 BR 112020000590A2 BR 112020000590 A BR112020000590 A BR 112020000590A BR 112020000590 A2 BR112020000590 A2 BR 112020000590A2
Authority
BR
Brazil
Prior art keywords
cancer
fsp
fsps
cvp
amino acids
Prior art date
Application number
BR112020000590-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Alfredo Nicosia
Elisa Scarselli
Guido Leoni
Armin Lahm
Original Assignee
Nouscom Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom Ag filed Critical Nouscom Ag
Publication of BR112020000590A2 publication Critical patent/BR112020000590A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10Sequence alignment; Homology search
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112020000590-8A 2017-07-12 2018-07-12 método de seleção de uma coleção, métodos para determinar as sequências de aminoácidos e para produzir uma cvp ou uma coleção de ácidos nucleicos, cvp, coleções de peptídeos de vacina, de ácidos nucleicos, de um ou mais vetores de expressão e coleção de vetores de expressão BR112020000590A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17181026 2017-07-12
EP17181026.0 2017-07-12
PCT/EP2018/069032 WO2019012082A1 (en) 2017-07-12 2018-07-12 UNIVERSAL VACCINE BASED ON SHARED TUMOR NEO-ANTIGENS FOR THE PREVENTION AND TREATMENT OF MICRO-SATELLITE INSTABILITY CANCER (MSI)

Publications (1)

Publication Number Publication Date
BR112020000590A2 true BR112020000590A2 (pt) 2020-07-14

Family

ID=59366234

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020000590-8A BR112020000590A2 (pt) 2017-07-12 2018-07-12 método de seleção de uma coleção, métodos para determinar as sequências de aminoácidos e para produzir uma cvp ou uma coleção de ácidos nucleicos, cvp, coleções de peptídeos de vacina, de ácidos nucleicos, de um ou mais vetores de expressão e coleção de vetores de expressão

Country Status (19)

Country Link
US (1) US11578109B2 (https=)
EP (1) EP3652606B1 (https=)
JP (1) JP7274223B2 (https=)
KR (1) KR102709778B1 (https=)
CN (1) CN111328420B (https=)
AU (1) AU2018298849B2 (https=)
BR (1) BR112020000590A2 (https=)
CA (1) CA3069047A1 (https=)
DK (1) DK3652606T5 (https=)
ES (1) ES2940087T3 (https=)
FI (1) FI3652606T3 (https=)
HU (1) HUE061840T2 (https=)
IL (1) IL271966B2 (https=)
MX (1) MX2020000413A (https=)
NZ (1) NZ759940A (https=)
PL (1) PL3652606T3 (https=)
PT (1) PT3652606T (https=)
SG (1) SG11202000250PA (https=)
WO (1) WO2019012082A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220349010A1 (en) * 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
CA3106564A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
IL280113B2 (en) 2018-07-26 2025-11-01 Curevac Netherlands B V Cancer vaccines for uterine cancer
WO2020022900A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
IL321692A (en) 2018-07-26 2025-08-01 Curevac Netherlands B V Cancer vaccines for colorectal cancer
WO2020022903A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
TWI852977B (zh) * 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020163802A1 (en) * 2019-02-07 2020-08-13 Arizona Board Of Regents On Behalf Of Arizona State University Cancer specific frameshift vaccines
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
US20230212243A1 (en) * 2020-05-12 2023-07-06 Institut Curie Neoantigenic Epitopes Associated with SF3B1 Mutations
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
JP2024516542A (ja) * 2021-04-06 2024-04-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Mhcクラスiペプチドを含む方法および組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
WO2003087162A2 (en) * 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
US20060160090A1 (en) * 2003-04-11 2006-07-20 Macina Robert A Composition splice variants and methods relating to cancer specific genes and proteins
CN1824325A (zh) * 2005-12-16 2006-08-30 武汉大学 人乳头病毒dna嵌合疫苗及制备方法和应用
KR101543622B1 (ko) * 2006-10-17 2015-08-11 온코세라피 사이언스 가부시키가이샤 Mphosph1 또는 depdc1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
CA2758356C (en) 2009-05-29 2016-07-26 Morphosys Ag A collection of vh and vl pairs having favourable biophysical properties and methods for its use
SG10201502791YA (en) * 2010-04-09 2015-05-28 Oncotherapy Science Inc Cdca5 Peptides And Vaccines Including The Same
CA2830787C (en) * 2011-03-24 2019-11-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dominant negative hsp110 mutant and its use in prognosing and treating cancers
JP5564730B2 (ja) * 2011-08-12 2014-08-06 オンコセラピー・サイエンス株式会社 Mphosph1ペプチドおよびそれを含むワクチン
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクRuprecht−Karls−Universitaet Heidelberg がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp)
US9205140B2 (en) * 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
CN104853764B (zh) * 2012-12-13 2018-06-22 海德堡吕布莱希特-卡尔斯大学 用于预防和治疗癌症的msi-特异性移码肽(fsp)
US20140235456A1 (en) * 2012-12-17 2014-08-21 Virginia Tech Intellectual Properties, Inc. Methods and Compositions for Identifying Global Microsatellite Instability and for Characterizing Informative Microsatellite Loci
US11098367B2 (en) * 2014-01-27 2021-08-24 Yale University Methods of identifying patients responsive to immunotherapeutic strategies
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
CN106350578A (zh) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques

Also Published As

Publication number Publication date
IL271966B1 (en) 2024-09-01
SG11202000250PA (en) 2020-02-27
US20200222519A1 (en) 2020-07-16
KR20200029443A (ko) 2020-03-18
EP3652606A1 (en) 2020-05-20
FI3652606T3 (fi) 2023-03-16
RU2019144505A3 (https=) 2021-08-12
NZ759940A (en) 2023-07-28
DK3652606T3 (da) 2023-03-13
CA3069047A1 (en) 2019-01-17
DK3652606T5 (da) 2024-08-26
JP2020532288A (ja) 2020-11-12
EP3652606B1 (en) 2023-01-11
MX2020000413A (es) 2020-09-28
HUE061840T2 (hu) 2023-08-28
IL271966B2 (en) 2025-01-01
WO2019012082A1 (en) 2019-01-17
RU2019144505A (ru) 2021-08-12
AU2018298849A1 (en) 2020-01-02
KR102709778B1 (ko) 2024-09-26
US11578109B2 (en) 2023-02-14
CN111328420A (zh) 2020-06-23
IL271966A (en) 2020-02-27
JP7274223B2 (ja) 2023-05-16
ES2940087T3 (es) 2023-05-03
PL3652606T3 (pl) 2023-04-24
PT3652606T (pt) 2023-03-16
WO2019012082A9 (en) 2019-05-02
CN111328420B (zh) 2023-07-25
AU2018298849B2 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
BR112020000590A2 (pt) método de seleção de uma coleção, métodos para determinar as sequências de aminoácidos e para produzir uma cvp ou uma coleção de ácidos nucleicos, cvp, coleções de peptídeos de vacina, de ácidos nucleicos, de um ou mais vetores de expressão e coleção de vetores de expressão
JP7554119B2 (ja) 共有抗原
TWI750122B (zh) 用於贅瘤疫苗之調配物及其製備方法
KR102429859B1 (ko) 신생물 백신을 위한 제형
CN107921117A (zh) Hpv疫苗
BR112015023524B1 (pt) Vírus vaccinia ankara modificado, composição compreendendo o dito vírus e uso do mesmo para primagem ou reforço de uma resposta imune
JP7298926B2 (ja) 癌の治療のためのネオアンチゲンワクチン組成物
US20230024133A1 (en) Prostate Neoantigens And Their Uses
AU2019361280B2 (en) Teleost invariant chain cancer vaccine
CN111670046A (zh) 疫苗的t细胞增强剂
CN115803049A (zh) 抗原编码盒
KR20230134138A (ko) 변형된 알파바이러스 벡터
US12295997B2 (en) Prostate neoantigens and their uses
JP7642608B2 (ja) ハンタウイルス抗原性組成物
HK40029760B (en) A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
HK40029760A (en) A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
RU2808567C2 (ru) Противораковая вакцина с инвариантной цепью из костистых рыб
RU2782261C2 (ru) Вакцинная композиция для лечения рака
CN121627808A (zh) Hpv-52型e6蛋白的特异性ctl表位肽及其应用

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]